This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
CD3 is the most clinically validated T-cell co-receptor target in oncology, with 1,023 drugs linked to it in the database and 12 FDA/EMA-approved bispecific T-cell engagers (TCEs) between 2014 and April 2025 — an unprecedented approval pace for any single target. The competitive arena is highly concentrated: Johnson & Johnson (Janssen), Amgen, Regeneron, and Roche/Genentech collectively hold 8 of the 12 approved drugs. Hematologic malignancies (multiple myeloma, B-cell lymphomas, ALL) have been the primary proving ground, but the frontier is now shifting toward solid tumors (SCLC, prostate cancer) and autoimmune diseases, where next-generation conditional/masked CD3 formats are generating intense deal activity. The patent landscape contains >18,000 families, with BiTE® antibody constructs (Amgen platform) representing the foundational IP cluster, while newer formats (half-life extended BiTEs, IgG-based bispecifics, activatable/masked CD3 antibodies) are rapidly expanding the IP space.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.
Arena Overview
Tier 3 — Challengers / Watchlist (China & Emerging)Zelgen/AbbVie deal\nChina | DLL3×CD3Cullinan/Genrix\nUSA/China | BCMA×CD3 (NDA)MacroGenics\nUSA | CD123×CD3Pfizer\nUSA | BCMA×CD3Tier 2 — Challengers (1 Approved + Active Phase 3)Genmab/AbbVie\nDenmark/USA | CD20×CD3AstraZeneca\nUK | CD19×CD3Boehringer Ingelheim\nGermany | DLL3×CD3Immunocore\nUK | CD3×gp100 (ImmTAC)Sanofi\nFrance | CD3 (anti-T1D)Tier 1 — Leaders (Multi-Approved + Deep Pipeline)Johnson & Johnson\nUSA | BCMA×CD3, GPRC5D×CD3, KLK2×CD3Amgen\nUSA | CD19×CD3, DLL3×CD3, STEAP1×CD3Regeneron\nUSA | CD20×CD3, BCMA×CD3Roche/Genentech\nSwitzerland/USA | CD20×CD3, FCRL5×CD3CD3 T-Cell Engager\nCompetitive Arena
Player Summary Table:
| Player | Region | Tier | Approved Drugs | Pipeline Highlights |
|---|---|---|---|---|
| Johnson & Johnson | USA | T1 | Teclistamab, Talquetamab | Pasritamig Ph3 (mCRPC), JNJ-79635322 Ph3 (MM) |
| Amgen | USA | T1 | Blinatumomab, Tarlatamab | Xaluritamig Ph3 (prostate), Obrixtamig Ph3 (SCLC) |
| Regeneron | USA | T1 | Odronextamab, Linvoseltamab | LINKER-MM5 Ph3 combo, Olympia-2/3 Ph3 |
| Roche/Genentech | Switzerland/USA | T1 | Mosunetuzumab, Glofitamab | Cevostamab Ph2 (MM, FCRL5), SUNMO Ph3 |
| Genmab/AbbVie | Denmark/USA | T2 | Epcoritamab | EPCORE FL-1 Ph3 (FL), DLBCL-1 negative |
| AstraZeneca | UK | T2 | — | Surovatamig Ph3 (CLL/SLL), SOUNDTRACK-D2 Ph3 |
| Boehringer Ingelheim | Germany | T2 | — | Obrixtamig Ph3 (SCLC + NEC) |
| Immunocore | UK | T2 | Tebentafusp | ImmTAC platform expansion (solid tumors) |
| Sanofi | France | T2 | Teplizumab | T1D Ph3 (stage 3 newly diagnosed) |
| Pfizer | USA | T3 | Elranatamab | Ph3 combo trials in MM |
| Zelgen (+ AbbVie option) | China | T3 | — | Alveltamig Ph3 (SCLC), AbbVie $1.235B deal |
| Cullinan/Genrix | USA/China | T3 | — | Velinotamig NDA/BLA filed (MM) |
Route Differentiation Analysis
The CD3 space has evolved across five distinct molecular routes:
| Player | BiTE (scFv) | IgG-like Bispecific | ImmTAC (TCR-based) | Anti-CD3 mAb (mono) | Next-Gen (Masked/Trispecific) |
|---|---|---|---|---|---|
| Amgen | Strong (BiTE® platform, blinatumomab, tarlatamab) | Moderate (HLE-BiTE) | — | — | Emerging (conditional BiTE) |
| J&J | — | Strong (IgG4-based: teclistamab, talquetamab, pasritamig) | — | — | Moderate (trispecific) |
| Regeneron | — | Strong (REGN format: odronextamab, linvoseltamab) | — | — | Moderate |
| Roche/Genentech | — | Strong (knobs-into-holes: mosunetuzumab, glofitamab) | — | — | Moderate (cevostamab) |
| Genmab/AbbVie | — | Strong (DuoBody® platform: epcoritamab) | — | — | Moderate |
| Immunocore | — | — | Strong (ImmTAC® TCR-bispecific: tebentafusp) | — | Emerging |
| Sanofi | — | — | — | Strong (teplizumab, anti-CD3ε) | Strong (tri-specific T-cell engager, Kali deal) |
| AstraZeneca | — | Strong (surovatamig, CD19×CD3) | — | — | Moderate |
| Boehringer Ingelheim | — | Strong (obrixtamig, DLL3×CD3) | — | — | Moderate |
| Zelgen | — | Moderate (alveltamig, DLL3×CD3) | — | — | — |
| Adagene/Third Arc | — | — | — | — | Strong (SAFEbody® masked CD3 TCE) |
Key route observations:
- BiTE® (Amgen): First-in-class, foundational IP (EP3411404A1 active) EP3411404A1. Short half-life is a limitation; Amgen has evolved to half-life-extended (HLE) BiTE formats.
- IgG-like bispecifics (J&J, Regeneron, Roche, Genmab): Dominant commercial format; subcutaneous dosing feasible; longer half-life; multiple approved products.
- ImmTAC® (Immunocore): Unique TCR-based CD3-redirecting format; only approved for uveal melanoma; 5-year OS data now available.
- Anti-CD3 mAb (Teplizumab): Entirely different mechanism — T-cell modulation/exhaustion for autoimmune disease (T1D), not tumor killing.
- Masked/conditional CD3 TCEs: Fastest-growing emerging route — Adagene SAFEbody®, Vir-5500 (PRO-XTEN), Enlaza War-Lock; aim to reduce CRS toxicity in solid tumors. Multiple deals in 2025–2026.
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Top Player Deep Dives
1. Johnson & Johnson (Janssen) — Tier 1 Leader
Portfolio: Teclistamab (BCMA×CD3, approved Aug 2022) , Talquetamab (GPRC5D×CD3, approved Aug 2023) , Pasritamig (KLK2×CD3, Phase 3 mCRPC).
Clinical signals: Teclistamab demonstrated superior PFS and OS vs. standard of care as early as first relapse in MM refractory to anti-CD38/lenalidomide (MAJESTIC-3 Ph3, positive). Teclistamab+Daratumumab combo also showed positive Ph3 data. Pasritamig (KLK2×CD3) is in two concurrent Phase 3 trials in mCRPC (KLK2-PASenger, KLK2-comPAS).
Route focus: IgG4-based bispecific format; subcutaneous administration; deep MM franchise with two distinct myeloma targets (BCMA, GPRC5D) and prostate cancer expansion (KLK2). J&J is the only company with two approved CD3 bispecifics in MM.
Trajectory: TRIlogy-4 and TRIlogy-5 Phase 3 trials compare new agent JNJ-79635322 head-to-head vs. teclistamab in RRMM.
2. Amgen — Tier 1 Leader
Portfolio: Blinatumomab (CD19×CD3, approved Dec 2014) , Tarlatamab (DLL3×CD3, approved May 2024) , Xaluritamig (STEAP1×CD3, Phase 3 prostate cancer).
Clinical signals: Tarlatamab Phase 3 in relapsed SCLC (DeLLphi-304 vs. SoC) and first-line SCLC combo (DeLLphi-312 + durvalumab/chemo). Blinatumomab SC vs. IV Phase 3 (AUDAX) ongoing.
Patent strength: Foundational BiTE® IP (EP3411404A1 active, Amgen Research Munich). EP3411404A1 PSMA×CD3 BiTE patent also active.
Route focus: Original BiTE® platform (scFv format); has evolved to HLE-BiTE for longer half-life. Expanding into solid tumors (SCLC via DLL3, prostate via STEAP1) — the broadest solid-tumor CD3 pipeline of any single company.
Trajectory: Xaluritamig Phase 3 (STEAP1×CD3 + abiraterone vs. investigator’s choice, chemo-naïve mCRPC) is Amgen’s highest-value near-term bet in solid tumors.
3. Regeneron — Tier 1 Leader
Portfolio: Odronextamab (CD20×CD3, approved Aug 2024) , Linvoseltamab (BCMA×CD3, approved Apr 2025).
Clinical signals: Odronextamab Olympia-2 (1L FL) and Olympia-3 (1L DLBCL) Phase 3 first results both positive. Linvoseltamab LINKER-MM5 Phase 3 combo vs. SoC regimens ongoing. Linvoseltamab also in smoldering MM (LINKER-SMM2).
Route focus: IgG-based bispecific platform; two distinct tumor types (B-cell lymphoma via CD20, MM via BCMA). Zai Lab partnership for China rights (odronextamab).
Trajectory: Regeneron is the fastest-growing CD3 franchise by recent approval pace (two approvals in ~8 months). Expanding odronextamab into 1L settings and combination regimens is the strategic priority.
4. Roche/Genentech — Tier 1 Leader
Portfolio: Mosunetuzumab (CD20×CD3, approved Jun 2022) , Glofitamab (CD20×CD3, approved Mar 2023) , Cevostamab (FCRL5×CD3, Phase 2 MM).
Clinical signals: SUNMO Phase 3 (mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R LBCL) — positive. Mosunetuzumab + polatuzumab vs. R-GemOx in aggressive B-NHL Phase 3 ongoing.
Route focus: Knobs-into-holes IgG bispecific platform; two CD20×CD3 products (differentiated by fixed-duration dosing for glofitamab vs. subcutaneous for mosunetuzumab). FCRL5 is a novel myeloma target being explored via cevostamab.
Trajectory: Roche is deepening the CD20×CD3 franchise via combination strategies (ADC+TCE) and exploring novel MM targets through FCRL5.
5. Genmab / AbbVie — Tier 2 Challenger
Portfolio: Epcoritamab (CD20×CD3, approved May 2023) via DuoBody® platform.
Clinical signals: EPCORE FL-1 Phase 3 (epcoritamab + R2 vs. R2 in R/R FL) — superior outcome, significant PFS benefit. However, EPCORE DLBCL-1 Phase 3 was negative — a setback for the DLBCL 3L+ indication.
Route focus: Subcutaneous DuoBody® bispecific; differentiated by SC delivery convenience. FL is now the primary commercial opportunity.
Trajectory: AbbVie’s commercial infrastructure is critical for epcoritamab’s global rollout. The DLBCL setback narrows the near-term indication scope.
6. AstraZeneca — Tier 2 Challenger
Portfolio: Surovatamig (CD19×CD3, Phase 3). Acquired via TeneoTwo acquisition.
Clinical signals: SOUNDTRACK-C1 Phase 3 in CLL/SLL with unmutated IGHV as consolidation therapy. SOUNDTRACK-D2 Phase 3 in 1L elderly/unfit LBCL (AZD0486).
Trajectory: AstraZeneca is entering the CD19×CD3 space in CLL — a differentiated indication from current CD20 bispecifics. This positions them in a less crowded niche.
7. Boehringer Ingelheim — Tier 2 Challenger
Portfolio: Obrixtamig (DLL3×CD3, Phase 3).
Clinical signals: DAREON-Lung-1 Phase 3 (obrixtamig + atezo/carbo/etoposide vs. SoC in ES-SCLC) recruiting. Also Phase 3 in extrapulmonary neuroendocrine carcinoma.
Trajectory: Competing head-to-head with Amgen’s tarlatamab in SCLC. Differentiator: combination with checkpoint inhibitor in 1L ES-SCLC vs. tarlatamab’s 2L+ positioning.
Indication Landscape & Target Pair Distribution
38%31%15%8%8%CD3 Bispecific Approved Drugs by Indication CategoryMultiple Myeloma [5]B-Cell Lymphoma [4]Leukemia (ALL/CLL) [1]Solid Tumor (SCLC/Melanoma) [2]Autoimmune (T1D) [1]
Phase 3 Pipeline by Indication:
| Indication | Key Drugs in Phase 3 | Companies |
|---|---|---|
| Multiple Myeloma | Teclistamab, Linvoseltamab, Velinotamig, JNJ-79635322 | J&J, Regeneron, Cullinan/Genrix |
| DLBCL / LBCL | Odronextamab, Mosunetuzumab, AZD0486 | Regeneron, Roche, AZ |
| Follicular Lymphoma | Odronextamab, Epcoritamab, TQB-2825 | Regeneron, Genmab/AbbVie, Chia Tai Tianqing |
| SCLC | Tarlatamab, Obrixtamig, Alveltamig, ZG006 | Amgen, BI, Zelgen, Zelgen |
| Prostate Cancer | Xaluritamig, Pasritamig | Amgen, J&J |
| CLL/SLL | Surovatamig | AstraZeneca |
| Type 1 Diabetes | Teplizumab | Sanofi |
| Neuroendocrine Carcinoma | Obrixtamig | Boehringer Ingelheim |
Domestic vs. Overseas Comparison
| Dimension | Western Players (USA/EU) | China Players |
|---|---|---|
| Approved drugs | 12 (all approved; Amgen, J&J, Regeneron, Roche, Genmab/AbbVie, Immunocore, Sanofi, Pfizer) | 0 approved globally (1 NDA filed: Velinotamig by Cullinan/Genrix) |
| Phase 3 count | ~20 trials | ~5–7 trials (ZG006/Alveltamig, TQB-2825, CM336, GR1803) |
| Technology routes | BiTE®, IgG bispecific, ImmTAC, masked/conditional TCE | IgG bispecific (majority); some BiTE-like formats |
| Platform innovation | High — activatable TCE, trispecific, TCR-based (ImmTAC) | Moderate — mostly IgG bispecific; emerging masked formats |
| Deal activity | Originator of most major deals | Increasingly licensing out to Western pharma (Zelgen→AbbVie $1.235B; Genrix→Cullinan; Antengene→UCB $1.18B) |
| Indication focus | Full spectrum (heme + solid + autoimmune) | Primarily heme malignancies; SCLC emerging |
| CRS management | Mature protocols; SC formulations reducing hospitalization | Evolving; mostly IV administration |
Key China-to-West licensing deals (2025–2026):
- Zelgen (Alveltamig, DLL3×CD3) → AbbVie: $100M upfront + $1.135B milestones
- Antengene (ATG-201, CD19×CD3) → UCB: $80M upfront + $1.1B milestones
- Kali Therapeutics (trispecific TCE) → Sanofi: $180M upfront + $1.05B milestones
China is rapidly becoming a licensing source for CD3 TCE assets, particularly in SCLC and autoimmune indications, reflecting strong preclinical/early-clinical capability but limited global commercial infrastructure.
Patent Landscape Highlights
The CD3 patent space contains >18,427 patent families (LS database). Key clusters:
| Patent Cluster | Representative | Assignee | Status |
|---|---|---|---|
| BiTE® foundational (CD3×tumor antigen, scFv) | EP3411404A1 (PSMA×CD3 BiTE) | Amgen Research (Munich) | Active |
| IgG-bispecific multispecific formats | EP2500354A3 | AbbVie | Inactive |
| CD3 bispecific anti-CD44v6 | WO2017055392A1 | Roche | PCT expired |
| Activatable/masked CD3 TCE (SAFEbody®) | WO2022171192A1 | Adagene | PCT expired |
| CAR-T / CD3ζ signaling domain | CN107207598A | 2Seventy Bio | Active |
EP3411404A1 WO2022171192A1
The most commercially relevant active IP sits with Amgen (BiTE® platform) and various IgG-bispecific format holders. The activatable/masked CD3 space is an emerging IP battleground with multiple filings from Adagene, Vir Biotechnology, and Enlaza Therapeutics in 2022–2026.
Risks, White Spaces & Strategic Observations
Key Competitive Risks
- CRS toxicity ceiling in solid tumors: The primary barrier to CD3 TCE expansion beyond hematology. Masked/conditional formats (SAFEbody®, PRO-XTEN) are the main technical response, but clinical validation is still early.
- Crowding in MM and B-cell lymphoma: BCMA×CD3 now has 3 approved drugs (teclistamab, elranatamab, linvoseltamab) and 1 NDA (velinotamig); differentiation on safety, dosing schedule, and combination strategy is critical.
- CD20×CD3 head-to-head pressure: Four approved agents (mosunetuzumab, glofitamab, epcoritamab, odronextamab) targeting the same antigen pair — commercial differentiation increasingly depends on delivery route (SC vs. IV), fixed-duration dosing, and combination compatibility.
- Epcoritamab DLBCL setback: The negative Phase 3 DLBCL-1 result signals that not all CD3 bispecific expansions into earlier lines will succeed.
White Spaces (Evidence-Backed)
| White Space | Rationale | Entry Path |
|---|---|---|
| Autoimmune diseases (beyond T1D) | Only teplizumab approved; multiple active deals (Sanofi trispecific, Galapagos/Gilead TCE, UCB/Antengene CD19×CD3) signal strong unmet need | CD19×CD3 or conditional CD3 formats; Sanofi, AZ, UCB are entering |
| Solid tumors beyond SCLC (GI, gynecologic) | SCLC is being addressed; colorectal, ovarian, pancreatic remain sparse | Novel tumor antigen pairs (e.g., CEA×CD3, MUC16×CD3); requires masked CD3 to manage toxicity |
| Combination TCE + ADC | Roche pioneering (mosunetuzumab + polatuzumab); synergy rationale strong but few dedicated combinations | Requires IP freedom-to-operate on combination regimen |
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Conclusion
Most competitive drugs by indication (as of April 2026):
- MM: Teclistamab (J&J) and Linvoseltamab (Regeneron) are the leading approved BCMA×CD3 agents; Talquetamab (J&J) is the only approved GPRC5D×CD3 agent with no direct competition yet.
- B-cell lymphoma: Odronextamab (Regeneron) has the most active Phase 3 expansion across 1L settings; Epcoritamab (Genmab/AbbVie) is the clear leader in FL after EPCORE FL-1 superior data.
- SCLC: Tarlatamab (Amgen) is first-approved and first-mover; obrixtamig (BI) and alveltamig (Zelgen/AbbVie) are Phase 3 challengers in 1L combination settings.
- Prostate cancer: No approved CD3 agent yet; Amgen (xaluritamig) and J&J (pasritamig) are the two Phase 3 frontrunners in mCRPC.
- Autoimmune: Teplizumab (Sanofi) is the only approved CD3 agent; the space is now attracting intense deal activity for next-generation formats.
Deepest pipeline company: Johnson & Johnson — two approved MM drugs, one Phase 3 prostate cancer drug, and two ongoing head-to-head Phase 3 trials testing next-generation MM agents.
Strongest emerging opportunity: The autoimmune T-cell engager space, where 3 major deals exceeding $1B in potential milestones were signed in Q1 2026 alone, signals that the next CD3 approval wave may come from autoimmune indications rather than oncology.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
